MCID: LRY044
MIFTS: 60

Larynx Cancer

Categories: Cancer diseases, Oral diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Larynx Cancer

MalaCards integrated aliases for Larynx Cancer:

Name: Larynx Cancer 12 15
Laryngeal Carcinoma 12 76 53 29 55 15
Laryngeal Cancer 53 37 55
Laryngeal Benign Neoplasm 12 15
Carcinoma of Larynx 12 73
Laryngeal Neoplasm 76 73
Malignant Neoplasm of Larynx 73
Laryngeal Neoplasms 44
Neoplasm of Larynx 12
Cancer, Laryngeal 40
Cancer of Larynx 12
Laryngeal Tumor 12
Larynx Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2596 DOID:2598 DOID:2600
ICD10 33 C32 C32.9
ICD9CM 35 161 161.9
MeSH 44 D007822
SNOMED-CT 68 93859007
KEGG 37 H00055

Summaries for Larynx Cancer

Disease Ontology : 12 A larynx cancer that has material basis in epithelial cells.

MalaCards based summary : Larynx Cancer, also known as laryngeal carcinoma, is related to laryngeal squamous cell carcinoma and verrucous carcinoma. An important gene associated with Larynx Cancer is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Endometrial cancer and Drug metabolism - cytochrome P450. The drugs Magnesium Sulfate and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and testes, and related phenotypes are Reduced mammosphere formation and digestive/alimentary

Wikipedia : 76 Laryngeal cancer, also known as cancer of the larynx or laryngeal carcinoma, are mostly squamous cell... more...

Related Diseases for Larynx Cancer

Diseases in the Larynx Cancer family:

Larynx Carcinoma in Situ

Diseases related to Larynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 237)
# Related Disease Score Top Affiliating Genes
1 laryngeal squamous cell carcinoma 31.3 CCND1 CDKN2A EGFR GSTM3 GSTT1 MIR21
2 verrucous carcinoma 30.2 CCND1 CDKN2A TP53
3 in situ carcinoma 29.9 CDKN2A EGFR TP53
4 asbestosis 29.8 GSTM1 GSTP1 GSTT1
5 inverted papilloma 29.7 CCND1 CDKN2A TP53
6 small cell carcinoma 29.7 CDKN2A EGFR TP53
7 malignant peritoneal mesothelioma 29.7 CDKN2A EGFR
8 oropharynx cancer 29.7 CCND1 CDKN2A EGFR TP53
9 basaloid squamous cell carcinoma 29.6 CDKN2A EGFR TP53
10 adenocarcinoma 29.4 CCND1 CDKN2A EGFR TP53
11 lynch syndrome 29.3 CCND1 CDKN2A EGFR GSTM1 TP53
12 squamous cell carcinoma 29.2 CCND1 CD44 CDKN2A EGFR GSTP1 MMP2
13 thyroid cancer 29.1 CCND1 EGFR GSTT1 TERT TP53
14 pancreatic cancer 29.0 CCND1 CD44 CDKN2A DLEU2 EGFR MIR21
15 nasopharyngeal carcinoma 28.8 CCND1 CDKN2A EGFR GSTM1 MMP2 NME1
16 ovarian cancer 28.6 CCND1 CD44 EGFR GSTP1 MIR21 MMP2
17 cervical cancer 28.4 CCND1 CD44 CDKN2A FHIT GSTM1 GSTP1
18 esophageal cancer 28.2 CCND1 CD44 CDKN2A EGFR FHIT GSTM1
19 lung cancer 28.1 CCND1 CD44 CDKN2A EGFR FHIT GSTM1
20 breast cancer 28.0 CCND1 CD44 CTSD EGFR FHIT GSTP1
21 laryngeal cancer, childhood 12.1
22 supraglottic laryngeal cancer 11.5
23 laryngeal neuroendocrine tumor 11.1
24 laryngeal mucoepidermoid carcinoma 11.1
25 laryngeal adenoid cystic carcinoma 11.1
26 laryngeal small cell carcinoma 11.1
27 larynx sarcoma 11.0
28 colorectal cancer, childhood 10.3 GSTM1 NAT2
29 hearing loss, noise-induced 10.3 GSTM1 GSTT1
30 sister chromatid exchange, frequency of 10.3 GSTM1 GSTT1
31 drug-induced hepatitis 10.3 GSTM1 GSTT1 NAT2
32 diffuse gastric cancer 10.2 GSTM1 GSTP1 GSTT1
33 xeroderma pigmentosum, complementation group d 10.2 GSTM1 GSTP1 GSTT1
34 breast papillomatosis 10.2 CCND1 CDKN2A
35 gastric adenosquamous carcinoma 10.2 CD44 CDKN2A TP53
36 tonsil squamous cell carcinoma 10.2 CCND1 CDKN2A
37 bladder squamous cell carcinoma 10.2 CDKN2A TP53
38 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
39 hypoxia 10.2
40 oral leukoplakia 10.2 CDKN2A GSTM1 GSTT1 TP53
41 male reproductive system disease 10.2 CCND1 GSTP1 TP53
42 spitz nevus 10.2 CDKN2A TP53
43 tongue disease 10.2 CDKN2A MMP2 TP53
44 cardia cancer 10.2 GSTM1 GSTP1 GSTT1 TP53
45 skin carcinoma in situ 10.2 CCND1 CDKN2A
46 acute lymphocytic leukemia 10.2 CDKN2A GSTM1 GSTT1 TP53
47 actinic keratosis 10.1 CDKN2A MMP2 TP53
48 nasopharyngeal disease 10.1 CCND1 CDKN2A TP53
49 retinal cancer 10.1 CCND1 CDKN2A TP53
50 ocular cancer 10.1 CCND1 CDKN2A TP53

Comorbidity relations with Larynx Cancer via Phenotypic Disease Network (PDN):


Bronchitis Deficiency Anemia
Pharynx Cancer Protein-Energy Malnutrition
Respiratory Failure Supraglottis Cancer
Swallowing Disorders

Graphical network of the top 20 diseases related to Larynx Cancer:



Diseases related to Larynx Cancer

Symptoms & Phenotypes for Larynx Cancer

GenomeRNAi Phenotypes related to Larynx Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCND1 CD44 EGFR GSTM1 GSTM3 MMP2

MGI Mouse Phenotypes related to Larynx Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.02 CCND1 CD44 CDKN2A CTSD EGFR ENG
2 hematopoietic system MP:0005397 10.02 CCND1 CD44 CDKN2A CTSD EGFR ENG
3 mortality/aging MP:0010768 9.93 CCND1 CD44 CDKN2A CTSD EGFR ENG
4 integument MP:0010771 9.91 CCND1 CD44 CDKN2A CTSD EGFR ENG
5 neoplasm MP:0002006 9.61 CCND1 CD44 CDKN2A EGFR FHIT MMP2
6 respiratory system MP:0005388 9.23 CCND1 CD44 CDKN2A EGFR ENG MMP2

Drugs & Therapeutics for Larynx Cancer

Drugs for Larynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
2
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
4
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
5 Analgesics Phase 4,Phase 1,Phase 2,Not Applicable
6 Anesthetics Phase 4,Not Applicable
7 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Central Nervous System Depressants Phase 4,Not Applicable
9 Liver Extracts Phase 4,Phase 2,Not Applicable
10 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
11 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable
12 Pharmaceutical Solutions Phase 4
13 calcium channel blockers Phase 4
14 Tocolytic Agents Phase 4
15 Calcium, Dietary Phase 4
16 Anticonvulsants Phase 4
17 Anti-Arrhythmia Agents Phase 4
18 Antidepressive Agents Phase 4,Phase 2
19 Antidepressive Agents, Second-Generation Phase 4,Phase 2
20 Dopamine Uptake Inhibitors Phase 4,Phase 2
21 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
22 Psychotropic Drugs Phase 4,Phase 2
23 Dopamine Agents Phase 4,Phase 2
24 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
25 Nicotinic Agonists Phase 4,Not Applicable
26 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
27 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
28 Central Nervous System Stimulants Phase 4,Not Applicable
29
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
30
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
31
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
32
Ethanol Approved Phase 3 64-17-5 702
33
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
34
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
35
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
36
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
37
Cefazolin Approved Phase 3 25953-19-9 656510 33255
38
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1 59-30-3 6037
40
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
41 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
42 Immunologic Factors Phase 3,Phase 2,Phase 1
43 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
44 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
45 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Not Applicable
47 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
48 Vasodilator Agents Phase 3
49 Vitamin B9 Phase 3,Phase 1
50 Vitamins Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 150)
# Name Status NCT ID Phase Drugs
1 Effect of Magnesium Sulphate Infusion on Lung Mechanics and Oxygenation in COPD Patients Undergoing Total Laryngeal Completed NCT03461328 Phase 4 Magnesium Sulphate
2 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
3 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
4 the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy Unknown status NCT00497588 Phase 3
5 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx Completed NCT00002496 Phase 3 chemotherapy;cisplatin;fluorouracil
6 Randomized Trial of ARCON in Larynx Cancer Completed NCT00147732 Phase 3
7 Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL
8 Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx Completed NCT00002839 Phase 3 cisplatin;fluorouracil
9 Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients Completed NCT00467948 Phase 3 cefazolin
10 Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Completed NCT00359645 Phase 3
11 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
12 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
13 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
14 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
15 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
16 Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
17 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
18 Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer Unknown status NCT01073683 Phase 2 Taxotere (Docetaxel), Cisplatin, 5FU
19 TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer Unknown status NCT00765011 Phase 2 TPF, radiotherapy and cetuximab
20 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx Unknown status NCT00004094 Phase 2 carboplatin;fluorouracil;hydroxyurea;paclitaxel
21 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
22 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
23 Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
24 Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
25 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
26 Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer Completed NCT00827164 Phase 2
27 Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer Completed NCT00004256 Phase 2
28 Clinical Feasibility of New Tracheoesophageal Puncture Set Completed NCT01045057 Phase 1, Phase 2
29 Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer Completed NCT02048020 Phase 2 paclitaxel;carboplatin
30 Endoscopic Surgery or Radiation Therapy in Treating Patients With Stage 0, Stage I, or Stage II Laryngeal Cancer of the Glottis Completed NCT00334997 Phase 2
31 Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx Completed NCT00243113 Phase 2 docetaxel
32 Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx Completed NCT00498953 Phase 1, Phase 2 carboplatin;cisplatin;docetaxel;fluorouracil;lapatinib ditosylate
33 Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation Completed NCT00169247 Phase 2 cetuximab;Cisplatin
34 Efficacy of Hyperbaric Oxygen Therapy in Laryngectomy Patients Completed NCT00026975 Phase 2
35 Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis Completed NCT00743262 Phase 1, Phase 2
36 A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab Completed NCT01435252 Phase 2 Cetuximab
37 Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer Completed NCT00014118 Phase 2 carboplatin;paclitaxel
38 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Completed NCT00970502 Phase 1, Phase 2 erlotinib + celecoxib
39 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer Completed NCT00462735 Phase 2 Cetuximab;Hydroxyurea;Fluorouracil
40 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Completed NCT00833261 Phase 2 cetuximab;cisplatin
41 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
42 Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer Completed NCT00002964 Phase 2 porfimer sodium
43 Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00002951 Phase 2 fluorouracil;hydroxyurea
44 Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract Completed NCT00524017 Phase 2
45 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Completed NCT00052611 Phase 2 Celecoxib
46 Bupropion in Helping Adults Stop Smoking Completed NCT00534001 Phase 2 bupropion hydrochloride
47 Zinc Supplements in Lowering Cadmium Levels in Smokers Completed NCT00376987 Phase 2
48 Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer Recruiting NCT02849314 Phase 1, Phase 2
49 Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer Recruiting NCT03759431 Phase 2
50 A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma Recruiting NCT02759575 Phase 1, Phase 2 Pembrolizumab;Cisplatin

Search NIH Clinical Center for Larynx Cancer

Cochrane evidence based reviews: laryngeal neoplasms

Genetic Tests for Larynx Cancer

Genetic tests related to Larynx Cancer:

# Genetic test Affiliating Genes
1 Laryngeal Carcinoma 29

Anatomical Context for Larynx Cancer

MalaCards organs/tissues related to Larynx Cancer:

41
Skin, Lymph Node, Testes, Lung, Thyroid, Endothelial, Breast

Publications for Larynx Cancer

Articles related to Larynx Cancer:

(show top 50) (show all 1225)
# Title Authors Year
1
Quality of life in patients with larynx cancer in Latin America: Comparison between laryngectomy and organ preservation protocols. ( 29554402 )
2018
2
Epidemiological features of cancers of the oral cavity, oropharynx, hypopharynx and larynx cancer in RAcunion Island. ( 29673737 )
2018
3
Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. ( 29598944 )
2018
4
Laryngeal Tuberculosis Mimicking Laryngeal Carcinoma on <sup>18</sup>F-FDG PET/CT Imaging. ( 29889030 )
2018
5
Comparative p16IKN4A Expression in Laryngeal Carcinoma and Cervical Cancer Precursors: A Real-time Grid-based Immunocytochemistry Analysis. ( 30275203 )
2018
6
Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients. ( 28685830 )
2018
7
Impact of HPV Status on the Prognostic Potential of the AJCC Staging System for Larynx Cancer. ( 29611770 )
2018
8
Does Socioeconomic Status Affect Stage at Presentation for Larynx Cancer in Canada's Universal Health Care System? ( 30200820 )
2018
9
Decision making in advanced larynx cancer: An evidenced based review. ( 30409301 )
2018
10
From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer. ( 30409302 )
2018
11
Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies. ( 30409316 )
2018
12
Association of Hospital Volume With Laryngectomy Outcomes in Patients With Larynx Cancer. ( 30476965 )
2018
13
Lemierre Syndrome as a Complication of Laryngeal Carcinoma. ( 29849275 )
2018
14
Neutrophil-Lymphocyte Ratio as a Prognostic Factor in Laryngeal Carcinoma. ( 29977836 )
2018
15
MicroRNA-138 inhibits proliferation and induces apoptosis of laryngeal carcinoma via targeting MAPK6. ( 30229830 )
2018
16
Prevention of anastomotic leak using an advanced pectoral flap in total pharyngolaryngectomy and free jejunal reconstruction for hypopharyngeal or laryngeal carcinoma. ( 30261803 )
2018
17
Human papillomavirus infection in patients with laryngeal carcinoma. ( 30342481 )
2018
18
Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration. ( 30361911 )
2018
19
Inhibition of GLUT-1 expression and the PI3K/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in vitro. ( 30464533 )
2018
20
Identification of Integrin β1 as a Novel PAG1-Interacting Protein Involved in the Inherent Radioresistance of Human Laryngeal Carcinoma. ( 30519312 )
2018
21
Survival analysis of distant metastasis of laryngeal carcinoma: analysis based on SEER database. ( 30542764 )
2018
22
Knockdown of DGCR5 enhances the radiosensitivity of human laryngeal carcinoma cells via inducing miR-195. ( 30549038 )
2018
23
EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma. ( 28795320 )
2018
24
Does CT help in predicting preepiglottic space invasion in laryngeal carcinoma? ( 28807527 )
2018
25
Prognostic significance of soft tissue deposits in laryngeal carcinoma. ( 28823696 )
2018
26
The incidence of thyroid cartilage invasion in early-stage laryngeal carcinoma: Our experience on sixty-two patients. ( 28994198 )
2018
27
Transoral laser surgery for laryngeal carcinoma: has Steiner achieved a genuine paradigm shift in oncological surgery? ( 29046085 )
2018
28
Altered O-glycosylation is associated with inherent radioresistance and malignancy of human laryngeal carcinoma. ( 29179977 )
2018
29
Beclin1 enhances cisplatin-induced apoptosis via Bcl-2-modulated autophagy in laryngeal carcinoma cells Hep-2. ( 29322787 )
2018
30
Feasibility of Salvage Selective Neck Dissection after Primary Irradiation of Pharyngeal and Laryngeal Carcinoma. ( 29428959 )
2018
31
NBS1 rs2735383 polymorphism is associated with an increased risk of laryngeal carcinoma. ( 29433451 )
2018
32
Fasudil inhibits proliferation and migration of Hep-2 laryngeal carcinoma cells. ( 29503530 )
2018
33
Variation in prognosis of early laryngeal carcinoma after different types of cordectomy with transoral laser microsurgery. ( 29504443 )
2018
34
TIMP-3 increases the chemosensitivity of laryngeal carcinoma to cisplatin via facilitating mitochondria-dependent apoptosis. ( 29523219 )
2018
35
The value of whole-body contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of patients with laryngeal carcinoma. ( 29533345 )
2018
36
MiR-632 promotes laryngeal carcinoma cell proliferation, migration and invasion through negative regulation of GSK3β. ( 29562960 )
2018
37
Laryngeal carcinoma in a father and son. Possible familial risk? ( 29619497 )
2018
38
Long non-coding RNA Dleu2 affects proliferation, migration and invasion ability of laryngeal carcinoma cells through triggering miR-16-1 pathway. ( 29687850 )
2018
39
High PINCH1 Expression in Human Laryngeal Carcinoma Associates with Poor Prognosis. ( 29755929 )
2018
40
Solitary femoral metastasis in a locoregionally controlled laryngeal carcinoma. ( 29761605 )
2018
41
Alterations in oxidative stress markers in laryngeal carcinoma patients. ( 29778552 )
2018
42
Oncological and functional outcomes of transoral laser surgery for laryngeal carcinoma. ( 29869708 )
2018
43
Combined treatment with acetazolamide and cisplatin enhances chemosensitivity in laryngeal carcinoma Hep-2 cells. ( 29928333 )
2018
44
Nuclear nonmetastatic protein 23-H1 expression and epithelial-mesenchymal transition in laryngeal carcinoma: A pilot investigation. ( 29953715 )
2018
45
Long non-coding RNA AFAP1-AS1/miR-320a/RBPJ axis regulates laryngeal carcinoma cell stemness and chemoresistance. ( 29971915 )
2018
46
Effects of Different Treatment Strategies and Tumor Stage on Survival of Patients with Advanced Laryngeal Carcinoma: A 15-Year Cohort Study. ( 29973955 )
2018
47
Downregulation of miRNA-26b inhibits cancer proliferation of laryngeal carcinoma through autophagy by targeting ULK2 and inactivation of the PTEN/AKT pathway. ( 28713931 )
2017
48
Salvage Surgery after Radiation Failure in T1/T2 Larynx Cancer: Outcomes following Total versus Conservation Surgery. ( 29292665 )
2017
49
MiR-503 enhances the radiosensitivity of laryngeal carcinoma cells via the inhibition of WEE1. ( 29019284 )
2017
50
Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells. ( 28123594 )
2017

Variations for Larynx Cancer

Cosmic variations for Larynx Cancer:

9 (show top 50) (show all 319)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6927812 ZFHX3 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.4946C>T p.S1649F 16:72797736-72797736 14
2 COSM45571 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.593A>G p.E198G 17:7674938-7674938 14
3 COSM10662 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 14
4 COSM10995 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.580C>T p.L194F 17:7674951-7674951 14
5 COSM11066 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.578A>T p.H193L 17:7674953-7674953 14
6 COSM10714 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.473G>T p.R158L 17:7675139-7675139 14
7 COSM43690 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.592G>A p.E198K 17:7674939-7674939 14
8 COSM10905 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 14
9 COSM10779 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.818G>T p.R273L 17:7673802-7673802 14
10 COSM10888 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.378C>A p.Y126* 17:7675234-7675234 14
11 COSM10808 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.488A>G p.Y163C 17:7675124-7675124 14
12 COSM6549 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.743G>T p.R248L 17:7674220-7674220 14
13 COSM12559 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.673-2A>T p.? 17:7674292-7674292 14
14 COSM43846 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.487T>C p.Y163H 17:7675125-7675125 14
15 COSM10893 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.824G>A p.C275Y 17:7673796-7673796 14
16 COSM10659 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 14
17 COSM44475 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.871A>T p.K291* 17:7673749-7673749 14
18 COSM10813 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.394A>G p.K132E 17:7675218-7675218 14
19 COSM11462 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.388C>G p.L130V 17:7675224-7675224 14
20 COSM44219 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.405C>G p.C135W 17:7675207-7675207 14
21 COSM6906 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.672+1G>A p.? 17:7674858-7674858 14
22 COSM44067 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.721T>A p.S241T 17:7674242-7674242 14
23 COSM11658 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.955A>T p.K319* 17:7673573-7673573 14
24 COSM44071 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.955A>G p.K319E 17:7673573-7673573 14
25 COSM11305 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.809T>C p.F270S 17:7673811-7673811 14
26 COSM44352 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.850A>C p.T284P 17:7673770-7673770 14
27 COSM43583 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.425C>T p.P142L 17:7675187-7675187 14
28 COSM10889 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 14
29 COSM10758 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 14
30 COSM10660 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 14
31 COSM10777 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.715A>G p.N239D 17:7674248-7674248 14
32 COSM10742 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.578A>G p.H193R 17:7674953-7674953 14
33 COSM44456 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.668C>A p.P223H 17:7674863-7674863 14
34 COSM11166 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.406C>T p.Q136* 17:7675206-7675206 14
35 COSM10810 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.725G>T p.C242F 17:7674238-7674238 14
36 COSM43949 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.401T>G p.F134C 17:7675211-7675211 14
37 COSM43935 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.577C>A p.H193N 17:7674954-7674954 14
38 COSM10645 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.527G>T p.C176F 17:7675085-7675085 14
39 COSM44103 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.737T>A p.M246K 17:7674226-7674226 14
40 COSM10654 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.637C>T p.R213* 17:7674894-7674894 14
41 COSM44143 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.919+1G>A p.? 17:7673700-7673700 14
42 COSM10648 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 14
43 COSM44278 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.791T>C p.L264P 17:7673829-7673829 14
44 COSM43826 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.706T>A p.Y236N 17:7674257-7674257 14
45 COSM98254 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.782+1G>A p.? 17:7674180-7674180 14
46 COSM11374 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.752T>A p.I251N 17:7674211-7674211 14
47 COSM44678 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.415A>T p.K139* 17:7675197-7675197 14
48 COSM43947 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 17:7674917-7674917 14
49 COSM45544 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.947C>T p.P316L 17:7673581-7673581 14
50 COSM11081 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 14

Expression for Larynx Cancer

Search GEO for disease gene expression data for Larynx Cancer.

Pathways for Larynx Cancer

Pathways related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.76 CCND1 CDKN2A EGFR GSTP1 HSP90AB1 TP53
2
Show member pathways
12.7 GSTM1 GSTM3 GSTP1 GSTT1 NAT2 NME1
3
Show member pathways
12.63 CCND1 CDKN2A EGFR FHIT MMP2 TP53
4
Show member pathways
12.58 CCND1 CDKN2A EGFR GSTM1 GSTM3 GSTP1
5 12.42 CCND1 CDKN2A GSTP1 TP53
6 12.39 CCND1 CD44 CDKN2A EGFR MIR21 TP53
7 12.34 CCND1 CDKN2A TERT TP53
8
Show member pathways
12.21 GSTM1 GSTM3 GSTP1 GSTT1
9 12.18 CCND1 CD44 EGFR MIR21 MMP2 TP53
10
Show member pathways
12.12 CCND1 EGFR HSP90AB1 TP53
11 12.09 CCND1 EGFR MMP2 TP53
12 12.08 CCND1 CDKN2A EGFR GSTM1 GSTM3 GSTP1
13 12.05 CCND1 EGFR HSP90AB1 TP53
14 12.02 GSTM1 GSTM3 GSTP1 HSP90AB1
15 11.97 CTSD EGFR MMP2 TP53
16 11.86 CD44 CDKN2A TP53
17 11.84 CCND1 CDKN2A EGFR TP53
18 11.79 CCND1 FHIT TP53
19 11.71 NME1 TERT TP53
20
Show member pathways
11.7 GSTM1 GSTP1 GSTT1
21 11.69 CCND1 MMP2 TERT
22 11.64 GSTM1 GSTM3 GSTP1 GSTT1 HSP90AB1 MMP2
23 11.63 CCND1 CDKN2A EGFR MMP2 TP53
24 11.61 CCND1 EGFR TERT
25 11.56 CD44 EGFR MMP2
26 11.5 CDKN2A GSTM1 GSTM3 GSTP1 GSTT1 TP53
27 11.47 CCND1 CD44 TP53
28 11.43 CCND1 CDKN2A EGFR MMP2 TP53
29
Show member pathways
11.39 GSTM1 GSTP1 NAT2
30 11.15 GSTM1 GSTP1 GSTT1
31 11.01 GSTM1 GSTP1 GSTT1
32 10.82 GSTP1 GSTT1

GO Terms for Larynx Cancer

Cellular components related to Larynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.8 CCND1 CDKN2A EGFR FHIT GSTM1 GSTM3
2 cytosol GO:0005829 9.44 CCND1 CD44 CDKN2A FHIT GSTM1 GSTM3

Biological processes related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.87 ENG MIR21 NME1 TERT
2 positive regulation of protein phosphorylation GO:0001934 9.8 CCND1 EGFR ENG MIR21
3 negative regulation of apoptotic process GO:0043066 9.8 CD44 EGFR GSTP1 HSP90AB1 MIR21 TERT
4 positive regulation of protein kinase B signaling GO:0051897 9.78 EGFR ENG HSP90AB1 MIR21
5 xenobiotic metabolic process GO:0006805 9.75 GSTP1 HSP90AB1 NAT2
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.73 CD44 EGFR HSP90AB1
7 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.63 MIR21 MMP2 TERT
8 cellular response to drug GO:0035690 9.62 EGFR HSP90AB1 NME1 TP53
9 positive regulation of superoxide anion generation GO:0032930 9.58 EGFR GSTP1
10 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.55 EGFR TP53
11 mitotic G1 DNA damage checkpoint GO:0031571 9.54 CCND1 TP53
12 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.52 ENG MIR21
13 xenobiotic catabolic process GO:0042178 9.51 GSTM1 GSTM3
14 nitrobenzene metabolic process GO:0018916 9.43 GSTM1 GSTM3
15 cellular detoxification of nitrogen compound GO:0070458 9.4 GSTM1 GSTM3
16 response to UV-A GO:0070141 9.37 CCND1 EGFR
17 replicative senescence GO:0090399 9.33 CDKN2A TERT TP53
18 glutathione metabolic process GO:0006749 9.26 GSTM1 GSTM3 GSTP1 GSTT1
19 glutathione derivative biosynthetic process GO:1901687 8.92 GSTM1 GSTM3 GSTP1 GSTT1

Molecular functions related to Larynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.86 EGFR ENG FHIT GSTM3 HSP90AB1 NME1
2 protein kinase binding GO:0019901 9.8 CCND1 CDKN2A EGFR GSTP1 HSP90AB1 TP53
3 ubiquitin protein ligase binding GO:0031625 9.73 EGFR FHIT HSP90AB1 TP53
4 enzyme binding GO:0019899 9.63 CCND1 EGFR GSTM1 GSTM3 NME1 TP53
5 disordered domain specific binding GO:0097718 9.54 CDKN2A HSP90AB1 TP53
6 nitric-oxide synthase regulator activity GO:0030235 9.4 EGFR HSP90AB1
7 glutathione binding GO:0043295 9.13 GSTM1 GSTM3 GSTP1
8 glutathione transferase activity GO:0004364 8.92 GSTM1 GSTM3 GSTP1 GSTT1

Sources for Larynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....